Patents by Inventor Svetlana Doronina

Svetlana Doronina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170216391
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Application
    Filed: February 17, 2015
    Publication date: August 3, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana Doronina, Robert Lyon, Peter Senter
  • Patent number: 9463252
    Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: October 11, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
  • Publication number: 20140050746
    Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.
    Type: Application
    Filed: October 23, 2013
    Publication date: February 20, 2014
    Applicant: Seattle Genetics, Inc.
    Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
  • Patent number: 8609105
    Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: December 17, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
  • Publication number: 20110020343
    Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.
    Type: Application
    Filed: March 18, 2009
    Publication date: January 27, 2011
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
  • Patent number: 7423116
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: September 9, 2008
    Assignee: Seattle Genetics Inc.
    Inventors: Svetlana Doronina, Peter D. Senter, Brian E. Toki
  • Publication number: 20080213289
    Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
    Type: Application
    Filed: January 18, 2008
    Publication date: September 4, 2008
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Svetlana Doronina, Brian E. Toki
  • Patent number: 7256257
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: August 14, 2007
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana Doronina, Peter D. Senter, Brian E. Toki
  • Publication number: 20070160617
    Abstract: This invention relates generally to antibody-drug conjugates (ADCs). In particular, the invention relates to ADCs which comprise an antibody or antigen-binding fragment thereof which binds to prostate-specific membrane antigen (PSMA) and is conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. The antibody-drug conjugate has a PC-3™ cell to C4-2 or LNCaP™ cell selectivity of at least 250. The invention also relates, in part, to compositions of and methods of using the ADCs. The methods provided include, for example, methods for treating a PSMA-mediated disease.
    Type: Application
    Filed: June 20, 2006
    Publication date: July 12, 2007
    Applicant: PSMA Development Company, LLC
    Inventors: Dangshe Ma, Paul Maddon, William Olson, Svetlana Doronina, Brian Toki, Peter Senter
  • Publication number: 20060229253
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Application
    Filed: June 12, 2006
    Publication date: October 12, 2006
    Inventors: Svetlana Doronina, Peter Senter, Brian Toki
  • Patent number: 7098308
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Grant
    Filed: November 1, 2004
    Date of Patent: August 29, 2006
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Brian E. Toki, Svetlana Doronina
  • Publication number: 20060074008
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 6, 2006
    Inventors: Peter Senter, Svetlana Doronina, Brian Toki
  • Publication number: 20050238649
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: November 5, 2004
    Publication date: October 27, 2005
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana Doronina, Peter Senter, Brian Toki, Allen Ebens, Toni Kline, Paul Polakis, Mark Sliwkowski, Susan Spencer
  • Publication number: 20050123536
    Abstract: The present invention relates to methods for the treatment of immunological disorders other than cancer, comprising administering proteins characterized by their ability to bind to CD30 and exert a cytostatic or cytotoxic effect on an activated lymphocyte. Such proteins include monoclonal antibodies AC10 and IleFi1. AC10 and HeFi-1 derivatives, and antibodies that compete with AC10 and HeFi-1 for binding to CD30. Other such proteins include multivalent anti-CD30 antibodies and anti-CD30 antibodies conjugated to cytotoxic agents. Treatment modalities with antibodies of the invention are also provided.
    Type: Application
    Filed: November 20, 2002
    Publication date: June 9, 2005
    Inventors: Che-Leung Law, Kerry Klussman, Alan Wahl, Peter Senter, Svetlana Doronina, Brian Toki
  • Publication number: 20050113308
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Application
    Filed: November 1, 2004
    Publication date: May 26, 2005
    Inventors: Peter Senter, Brian Toki, Svetlana Doronina
  • Patent number: 6884869
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: April 26, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Brian E. Toki, Svetlana Doronina
  • Publication number: 20050009751
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Application
    Filed: November 1, 2001
    Publication date: January 13, 2005
    Inventors: Peter Senter, Brian Toki, Svetlana Doronina
  • Publication number: 20040157782
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Application
    Filed: March 29, 2004
    Publication date: August 12, 2004
    Inventors: Svetlana Doronina, Peter D. Senter, Brian E. Toki
  • Publication number: 20030083263
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity, and/or include a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody.
    Type: Application
    Filed: April 30, 2001
    Publication date: May 1, 2003
    Inventors: Svetlana Doronina, Brian Toki, Peter Senter